Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOther Accumulated ExpensesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioregenx (BRGX) Total Current Liabilities (2021 - 2025)

Bioregenx's Total Current Liabilities history spans 5 years, with the latest figure at $4.1 million for Q4 2025.

  • Quarterly results put Total Current Liabilities at $4.1 million for Q4 2025, up 11.92% from a year ago — trailing twelve months through Dec 2025 was $4.1 million (up 11.92% YoY), and the annual figure for FY2025 was $4.1 million, up 11.92%.
  • Total Current Liabilities for Q4 2025 was $4.1 million at Bioregenx, up from $3.9 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $4.1 million in Q4 2025 to a low of $14159.0 in Q4 2021.
  • The 5-year median for Total Current Liabilities is $3.4 million (2024), against an average of $2.3 million.
  • The sharpest move saw Total Current Liabilities soared 8553.83% in 2024, then increased 11.81% in 2025.
  • Year by year, Total Current Liabilities stood at $14159.0 in 2021, then skyrocketed by 358.22% to $64880.0 in 2022, then skyrocketed by 4195.9% to $2.8 million in 2023, then soared by 30.35% to $3.6 million in 2024, then grew by 11.92% to $4.1 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $4.1 million, $3.9 million, and $3.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.